Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial.

Abbas Z, Yakoob J, Jafri W, Ahmad Z, Azam Z, Usman MW, Shamim S, Islam M.

Eur J Gastroenterol Hepatol. 2014 Jun;26(6):630-9. doi: 10.1097/MEG.0000000000000094.

PMID:
24722560
2.

A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life.

Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ.

J Clin Gastroenterol. 2011 Sep;45(8):679-83. doi: 10.1097/MCG.0b013e318204593e. Erratum in: J Clin Gastroenterol. 2011 Oct;45(9):838.

PMID:
21301358
3.

Role of Saccharomyces boulardii in diarrhea predominant irritable bowel syndrome.

Kabir MA, Ishaque SM, Ali MS, Mahmuduzzaman M, Hasan M.

Mymensingh Med J. 2011 Jul;20(3):397-401.

PMID:
21804501
4.

The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.

Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS, Seo JG.

J Clin Gastroenterol. 2012 Mar;46(3):220-7. doi: 10.1097/MCG.0b013e31823712b1.

PMID:
22157240
5.

Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.

Bafutto M, Almeida JR, Leite NV, Costa MB, Oliveira EC, Resende-Filho J.

Arq Gastroenterol. 2013 Oct-Dec;50(4):304-9. doi: 10.1590/S0004-28032013000400012.

6.

I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life.

Lorenzo-Zúñiga V, Llop E, Suárez C, Alvarez B, Abreu L, Espadaler J, Serra J.

World J Gastroenterol. 2014 Jul 14;20(26):8709-16. doi: 10.3748/wjg.v20.i26.8709.

7.

A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.

Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P.

Gastroenterol Clin Biol. 2008 Feb;32(2):147-52. doi: 10.1016/j.gcb.2007.06.001.

8.

Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome.

Dolin BJ.

Methods Find Exp Clin Pharmacol. 2009 Dec;31(10):655-9. doi: 10.1358/mf.2009.31.10.1441078.

PMID:
20140275
9.
10.

Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial.

Pozzoni P, Riva A, Bellatorre AG, Amigoni M, Redaelli E, Ronchetti A, Stefani M, Tironi R, Molteni EE, Conte D, Casazza G, Colli A.

Am J Gastroenterol. 2012 Jun;107(6):922-31. doi: 10.1038/ajg.2012.56.

PMID:
22472744
11.

Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind study.

Sisson G, Ayis S, Sherwood RA, Bjarnason I.

Aliment Pharmacol Ther. 2014 Jul;40(1):51-62. doi: 10.1111/apt.12787.

12.

Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study.

Guglielmetti S, Mora D, Gschwender M, Popp K.

Aliment Pharmacol Ther. 2011 May;33(10):1123-32. doi: 10.1111/j.1365-2036.2011.04633.x.

13.

Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome--a pilot study.

Tuteja AK, Fang JC, Al-Suqi M, Stoddard GJ, Hale DC.

Scand J Gastroenterol. 2012 Oct;47(10):1159-64.

PMID:
22783919
14.
15.

Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study.

Majeed M, Nagabhushanam K, Natarajan S, Sivakumar A, Ali F, Pande A, Majeed S, Karri SK.

Nutr J. 2016 Feb 27;15:21. doi: 10.1186/s12937-016-0140-6.

17.
18.

A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome.

Roberts LM, McCahon D, Holder R, Wilson S, Hobbs FD.

BMC Gastroenterol. 2013 Mar 7;13:45. doi: 10.1186/1471-230X-13-45.

19.

Clinical trial: transcutaneous interferential electrical stimulation in individuals with irritable bowel syndrome - a prospective double-blind randomized study.

Coban Ş, Akbal E, Köklü S, Köklü G, Ulaşlı MA, Erkeç S, Aktaş B, Yüksel O, Koçak E, Erdem HR.

Digestion. 2012;86(2):86-93. doi: 10.1159/000338301.

PMID:
22846190
20.

Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles.

O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM.

Gastroenterology. 2005 Mar;128(3):541-51.

PMID:
15765388
Items per page

Supplemental Content

Support Center